⭐Popular

Survodutide

Also known as: BI 456906

Weight LossPerformanceHealth
Not FDA Approved

Primary recreational use: Weight loss

What is Survodutide?

Survodutide, also known as BI 456906, is a dual GLP-1/glucagon receptor agonist developed for the treatment of obesity and metabolic diseases such as NASH. It is currently in Phase 3 clinical trials and is not yet FDA-approved. This peptide is notable for its ability to suppress appetite while increasing energy expenditure, with significant weight and liver fat reduction observed in trials. Users should be cautious due to common gastrointestinal side effects.

Primary Benefits

Promotes fat loss. Improves metabolic function. Reduces liver fat.

How It Works

Survodutide acts on both GLP-1 and glucagon receptors, achieving appetite suppression and improved glucose control via GLP-1, while glucagon receptor activity increases metabolic rate and reduces liver fat. The dual action facilitates sustained weight loss and metabolic improvements.

Safety Tips

Precautions reported in community discussions and literature. This is not a complete list.

  • 1.DON'T start with a high dose - begin with titration to assess tolerance.
  • 2.DON'T ignore gastrointestinal side effects - consult healthcare provider if severe.
  • 3.DON'T skip doses frequently - maintain consistent weekly schedule.
  • 4.DON'T mix with other glucagon agonists without medical advice.
  • 5.DON'T use during pregnancy or breastfeeding.

Who Should NOT Use

  • Pregnancy
  • Breastfeeding
  • Severe gastrointestinal disease

Use Contexts

Different purposes have different protocols, dosing, and considerations

🔬Investigational

Obesity treatment

strong evidence

Investigated for significant weight loss in both diabetic and non-diabetic obese patients.

Evidence: Phase 2 and 3 trials indicate significant weight loss effects in obese patients without diabetes at doses between 2.4 mg to 6.0 mg weekly.

The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.

Reported Range
0.6-6 mg
Reported Frequency
once weekly
Reported Cycle
24-76 weeks
Reported Route
Subcutaneous

Timing: Any time of day, consistency recommended

Notes: Initiate with low dose and titrate based on tolerance. Long-term therapy likely.

Community-Reported Protocols

Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.

Reported GoalReported DoseReported FrequencyReported Route
Obesity - Conservative Start0.6mg titrated over 24 weeksOnce weekly with 4-week intervalsSubcutaneous
Obesity - Standard Protocol3.6-6.0mgOnce weeklySubcutaneous

Pharmacokinetics

Half-Life
6.5 days
Time to Peak
2 days
Clearance
~32.5 days

Reported Side Effects

This is not a complete list. Other side effects may occur.

Common
Nauseavery common (>10%)
Vomitingcommon (1-10%)
Diarrheacommon (1-10%)
Constipationreported (frequency unknown)
Serious / Rare
  • Increased heart rate
Injection-Specific Warnings
  • Use sterile technique to prevent infection
  • Rotate injection sites to avoid irritation

Storage

Temperature
2-8°C
Reconstituted
Store in refrigerator immediately
Shelf Life
4 weeks after reconstitution
Light Sensitive
Yes - protect from light
🔬Investigational

Type 2 Diabetes management

strong evidence

Studied for glucose control and weight loss in Type 2 Diabetics.

Evidence: Effective in weight and glucose control with a head-to-head advantage over semaglutide.

The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.

Reported Range
0.3-2.7 mg
Reported Frequency
once weekly
Reported Cycle
16-48 weeks
Reported Route
Subcutaneous

Timing: Same day each week

Notes: No dose adjustment needed in hepatic impairment.

Community-Reported Protocols

Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.

Reported GoalReported DoseReported FrequencyReported Route
Type 2 Diabetes0.3-2.7mgOnce weeklySubcutaneous

Pharmacokinetics

Half-Life
6.5 days
Time to Peak
2 days
Clearance
~32.5 days

Reported Side Effects

This is not a complete list. Other side effects may occur.

Common
Hypoglycemia (with concurrent diabetes meds)reported (frequency unknown)
Injection-Specific Warnings
  • Monitor blood glucose levels if on diabetes meds

Storage

Temperature
2-8°C
Reconstituted
Store in refrigerator
Shelf Life
4 weeks after reconstitution
Light Sensitive
Yes - protect from light

Harm Reduction Information

Quality Concerns

  • Ensure vials are sealed and stoppers intact before use
  • Check expiration dates of both peptide and bacteriostatic water

Safety Tips

  • Use bacteriostatic water for reconstitution
  • Allow solutions to settle after mixing to avoid injecting foam
  • Rotate injection sites to prevent tissue damage
  • Start with the lowest effective dose to monitor tolerance

Warning Signs to Stop

  • Severe persistent gastrointestinal discomfort
  • Unexpected heart rate changes
  • Allergic reaction symptoms

Seek Medical Help Immediately If

  • Severe allergic reaction
  • Symptoms of overdose

Frequently Asked Questions

Common questions about Survodutide

How long until I see effects?

With Survodutide, initial weight loss may begin between weeks 4 and 8, with more significant effects around week 24.

What time of day should I take it?

Survodutide can be administered at any time of day, but consistency with timing each week is recommended.

How can I minimize side effects?

To minimize side effects of Survodutide, start with a lower dose and titrate up slowly while monitoring for gastrointestinal issues.

Does tolerance develop?

There is no significant evidence to suggest tolerance develops with Survodutide when used correctly.

How should I store it?

Store Survodutide at 2-8°C and protect from light. Use it within 4 weeks after reconstitution.

Do I need to cycle it?

Survodutide is intended for long-term continuous use, so cycling is not generally required.

Reported Combinations

Compounds reported to be used alongside Survodutide in community discussions

investigational

Semaglutide

Complement GLP-1 effects for enhanced glucose control

investigational

Tirzepatide

Similar mechanisms may offer synergistic metabolic benefits

investigational

Metformin

Common staple in diabetes management enhancing glucose effects

Reported Interactions

Interactions reported in literature and community discussions.

Semaglutide/Tirzepatidemajor

Avoid combining due to similar mechanisms.

Metforminmoderate

Monitor blood glucose levels as combination may potentiate effects.

SGLT2 Inhibitorsminor

Compatible, but monitor for enhanced glucose control.

Warfarinmoderate

Requires monitoring when combined.

Oral Contraceptivesminor

Time administration as needed to ensure effectiveness.

Reconstitution Calculator

mL
U100 insulin syringe01020304050607080901001mL

100 units = 1 mL

Safety Tips

  • Always consult a licensed medical professional for dosing and reconstitution instructions.
  • Always double check your units. Mixing up mg and mcg can be very dangerous.
  • Make sure to select your syringe type. U-100 and U-50 syringes have different units.
  • Ensure you're not adding more BAC than your vial can hold. Most vials have maximum capacities listed.

This calculator is for informational and educational purposes only. It does not provide medical advice, dosing recommendations, or safety determinations. Reference ranges shown are compiled from publicly available sources and are not a substitute for guidance from a licensed healthcare professional.

Explore More Research

Browse our database of peptide research information compiled from published literature and community sources.

Browse All PeptidesAbout Pepbase App

Citations

Last updated: October 2, 2023

Important Disclaimer

AI-Generated Content Notice

The information on this page has been compiled using artificial intelligence (AI) and large language model (LLM) technology from multiple sources including published literature, online communities, and public databases. This content may contain errors, inaccuracies, outdated information, or omissions. We make no guarantees regarding the accuracy, completeness, or reliability of any information presented. You are solely responsible for independently verifying any information before relying on it.

Not Medical Advice

Nothing on this website constitutes medical advice, diagnosis, or treatment recommendations. The information provided is for educational and harm-reduction purposes only. We do not provide individualized dosing guidance or treatment recommendations. Protocols and dosing information shown represent reports from community discussions and published literature—they are not endorsements or recommendations. Always consult with a licensed healthcare professional before making any health-related decisions.

No Endorsement of Use

Pepbase does not endorse, encourage, or recommend the use of any peptide or substance discussed on this website. Many compounds discussed are not approved for human use by the FDA or other regulatory agencies. Some substances may be illegal to possess, sell, or use in your jurisdiction. We do not facilitate or encourage the procurement, distribution, or use of controlled or prescription-only substances. Users are solely responsible for understanding and complying with all applicable laws in their jurisdiction.

Calculators and Tools

Any calculators, estimators, or tools provided on this website are for informational purposes only and produce estimates that may be inaccurate. Errors in calculations can result in serious harm. You are solely responsible for verifying all calculations independently. These tools do not account for individual factors that may affect dosing and should never be relied upon as a substitute for professional medical guidance.

Assumption of Risk

By using this website, you acknowledge that you understand the risks associated with using unregulated substances and that you assume full responsibility for your own health decisions. Pepbase, its creators, contributors, and affiliates disclaim all liability for any harm, injury, or damages arising from the use or misuse of information on this website. Use of any information on this site is entirely at your own risk.

If you are experiencing a medical emergency, call emergency services immediately. If you have questions about medications or supplements, consult a licensed pharmacist or physician.